Diabetes: new conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra


The PPAR gamma nuclear receptor orchestrates fatty acid storage and glucose metabolism by coordinating the expression of genes involved in lipid uptake, adipogenesis and inflammation. It is a target for the insulin-sensitising thiazolidinediones (TZDs) which have been used to treat diabetes since the late nineties. Adverse secondary effects of TZDs have underpinned continued investigations into the molecular details governing PPAR gamma regulation and new therapeutic approaches which represent the focus of this article. Recent findings position Cdk5 as a lead conductor of PPAR gamma. Cdk5 regulates PPAR gamma directly, via phosphorylation, and may also inhibit it indirectly, via phosphorylation and activation of phospholipase D2 (PLD2) which generates the endogenous inhibitor cyclic phosphatidic acid (CPA). Whilst the multifunctional nature of Cdk5 precludes it from therapeutic targeting all is not lost as selective PPAR gamma modulators (SPPARMs) have shown promising preclinical and clinical results heralding a new generation of drugs to conduct a more refined PPAR gamma program. (C) 2011 Elsevier Ltd. All rights reserved

Similar works

Full text


University of Queensland eSpace

Full text is not available
oai:espace.library.uq.edu.au:UQ:695014Last time updated on 12/4/2017

This paper was published in University of Queensland eSpace.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.